<DOC>
	<DOCNO>NCT02965443</DOCNO>
	<brief_summary>To perform study investigates effectiveness add SGLT2 inhibitor dapagliflozin + DPP-4 inhibitor saxagliptin v placebo revert BBIT regimen BOT regimen patient type 2 diabetes .</brief_summary>
	<brief_title>Dapagliflozin + Saxagliptin Basal-bolus Insulin Treatment</brief_title>
	<detailed_description>This phase IV study investigate efficacy safety add SGLT2 inhibitor dapagliflozin together wih DPP-4 inhibitor saxagliptin intensified insulin treatment regimen . Because BOT superior BBIT respect development bodyweight , hypoglycaemia patient satisfaction type 2 diabetes , hypothesize combine addition SGLT2 inhibitor dapagliflozin DPP-4 inhibitor saxagliptin effective safe revert BBIT BOT treatment regimen .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Type 2 diabetes Age 18 75 year AntiGAD antibody negative Cpeptide level ≥ 1.5 ng/mL Fasting blood glucose &gt; 126 mg/dl HbA1c 8.0 10.5 % BMI 25.0 45.0 kg/m2 Previous therapy BBIT ( basal insulin least daily bolus insulin ) Use oral antidiabetic treatment except metformin ( i.e. , sulphonylureas , DPPIV inhibitor , thiazolidinediones , SGLT2 inhibitor ) GLP1 analogue within last three month prior Screening Repeated episode severe hypoglycaemia within last six month prior Screening History diabetic ketoacidosis , praecoma diabeticum , diabetic coma Treatment investigational drug within last three month Screening Acute infection within last four week prior Screening Recurrent urogenital infection History pancreatitis Anamnestic history hypersensitivity study drug drug similar chemical structure History severe multiple allergy Concomitant participation clinical trial Type 1 diabetes Cardiovascular disease Clinically relevant ventricular tachycardia ventricular fibrillation , 3rd degree AV block Torsades de Pointes treatment antiarrhythmic drug . Percutaneous coronary intervention within past 6 month . Any follow within past 6 month : myocardial infarction ( MI ) , coronary artery bypass surgery ; unstable angina ; stroke . Uncontrolled unstable angina pectoris history pericarditis , myocarditis , endocarditis . Congestive heart failure NYHA class III IV . Increased risk thromboembolism , e.g . subject history deep leg vein thrombosis family history deep leg vein thrombosis , judge Investigator . Malignancy include leukemia lymphoma within last 5y . Liver disease cirrhosis chronic active hepatitis . Significant renal dysfunction ( see also exclusion criterion laboratory abnormality ) . State kidney transplantation Endocrine disease : Acromegaly treatment growth hormone similar drug . Chronic oral parenteral corticosteroid treatment ( &gt; 7 consecutive day treatment ) within 8 week ; thyroid hormone replacement allow dosage stable least 3 month TSH within normal limit •Any follow significant laboratory abnormality : eGFR ( calculate MDRD equation ) &lt; 60 ml/min Screening Fasting triglyceride &gt; 700 mg/dl ( &gt; 7.9 mmol/l ) Systolic blood pressure outside range 100160 mmHg diastolic blood pressure 95 mmHg Screening History active substance abuse ( include alcohol &gt; 40g/day ) within past 2 year . Pregnancy childbearing potential without adequate contraception Present therapy systemic steroid Presence psychiatric disorder intake antidepressive antipsychotic agent exception benzodiazepine SSRIs/SNRI´s Potentially unreliable subject , judge investigator unsuitable study . Contraindications Magnetic resonance ( MR ) scan person cardiac pacemaker implant metal claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>